New therapeutical measures in diabetes
DOI:
https://doi.org/10.47196/diab.v47i3.210Keywords:
diabetes, therapeuticalAbstract
Diabetes is not an innocuous disease and its presence is intimately linked to its specific complications and the first causes of mortality, such as cardiovascular pathologies.
These factors - the high prevalence of the disease and its natural history - have been the primary engine for the health authorities and the pharmaceutical industry to try to find useful measures for the prevention and treatment of this pathology.
References
- American Diabetes Association. American Diabetes Association Calls for independent review of incretin therapy. ADA, Alexandria. VA. June 10, 2013.
- Andrianesis V, Doupis J. The role of Kidney in glucose homeostasis. SGLT 2 Inhibitors, a new approach in Diabetes treatment. Expert Rev. Clin. Pharmacol 2013; 6: 519-539.
- Gorboulev V, Schürmanss A, Vallon V. et al. Nat-Glucose-Cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion/ Diabetes 2012; 61: 187-196.
- Abbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 2008, 62: 1279-1284.
- Nainggolan L. Fungal Infections with new Diabetes drugs “Manageable”. Jul 03, 2013 Medscape Medical News. www.mediscape.com.
- Pollack A. A lone voice raises alarms on lucrative diabetes drugs. The New York times, May 30, 2013.
- Tucker ME. Experts Express Mixed thoughts on Canaglifozin Approval. April 18, 2013. Medscope Medical News. www.medscape.com.
- Tucker ME. Rosiglitazone restrictions should be eased, FDA panel ˃ayn. Jul 06, 2013 Mediscape Medical News. www. medscape.com.
- Vick H, Diedrich DF, Baumann K. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J. Physiol. 1973; 224: 552-557.
- Yanina Pepino M, Tiemann CD, Patterson BW, Wice BM, Klein S. Diabetes Care published ahead of print April 30, 2013.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
